Provided by Tiger Trade Technology Pte. Ltd.

Minerva Neurosciences

2.52
-0.3750-12.98%
Post-market: 2.520.00000.00%16:20 EDT
Volume:184.67K
Turnover:477.89K
Market Cap:120.09M
PE:-0.09
High:3.08
Open:2.88
Low:2.51
Close:2.89
52wk High:12.46
52wk Low:2.24
Shares:47.75M
Float Shares:34.30M
Volume Ratio:1.46
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-28.4557
EPS(LYR):-34.6700
ROE:-675.09%
ROA:-28.42%
PB:-0.56
PE(LYR):-0.07

Loading ...

Minerva Neurosciences to Join Wells Fargo Healthcare Conference for Investor Meetings

Reuters
·
Aug 28

Minerva Neurosciences Files Form 3 for Chief Accounting Officer Anthony Aliquo

Reuters
·
Aug 21

Minerva Neurosciences Raised to Buy from Hold by Jefferies

Dow Jones
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Kyntra Bio (KYNB) and Minerva Neurosciences (NERV)

TIPRANKS
·
Aug 14

U.S. Research Roundup-Cisco, Fox Corp, Target

Reuters
·
Aug 14

Minerva Neurosciences, Inc : Jefferies Raises to Buy from Hold; Raises Target Price to $10 from $7.5

THOMSON REUTERS
·
Aug 14

Minerva Neurosciences Elevates Aliquo to Accounting Leadership

TIPRANKS
·
Aug 13

Minerva Neurosciences Names Anthony Aliquo Chief Accounting Officer

Reuters
·
Aug 13

Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate

Benzinga Earnings
·
Aug 07

Minerva Neurosciences Returns to GAAP Profit in Q2 FY26 at $17.47 Million; GAAP Net Loss Widens to $107.94 Million in H1 FY26

Reuters
·
Aug 07

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

THOMSON REUTERS
·
Aug 07

Minerva Neurosciences releases corporate presentation on roluperidone for negative symptoms of schizophrenia

Reuters
·
Jun 05

Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting

TIPRANKS
·
Jun 05

Minerva Neurosciences shareholders approve charter amendments at annual meeting

Reuters
·
Jun 05

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

THOMSON REUTERS
·
Jun 02

Minerva Neurosciences - Topline Data From 12-Week Phase a Expected in Second Half of 2027

THOMSON REUTERS
·
Jun 02

Minerva Neurosciences forms scientific advisory board for roluperidone program

Reuters
·
Jun 02

Minerva Neurosciences enters equity distribution deal for up to $75 million ATM offering

Reuters
·
May 28

Minerva Neurosciences - to Offer and Sell up to $75 Mln in Common Stock Through Leerink Partners - SEC Filing

THOMSON REUTERS
·
May 28

Minerva Neurosciences publishes corporate presentation on roluperidone for schizophrenia negative symptoms

Reuters
·
May 20